Tarsus Pharmaceuticals Inc (TARS)
49.22
+2.72
(+5.85%)
USD |
NASDAQ |
Nov 14, 10:36
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.872B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 170.8% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 20.23 |
| Price to Book Value | 7.423 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.2838 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. |
| URL | https://www.tarsusrx.com |
| Investor Relations URL | https://ir.tarsusrx.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Feb. 27, 2025 (est.) |
| Last Earnings Release | Nov. 13, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. |
| URL | https://www.tarsusrx.com |
| Investor Relations URL | https://ir.tarsusrx.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Feb. 27, 2025 (est.) |
| Last Earnings Release | Nov. 13, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |